Industry leaders reject calls for permanent adoption of IP waiver for future pandemics

“As we address the equity challenge, we must not lose sight of the innovation delivered in response to COVID‐19, with pharmaceutical companies producing billions of safe and effective vaccines and therapeutics at a speed very few thought possible,” wrote the industry leaders. …